Biotech Startups

Cytochroma provides genetically diverse iPSC-derived human cell models, high-throughput screening, and phenotypic data (branded "Wet AI") for drug discovery and preclinical validation. It serves pharmaceutical and biotech teams seeking donor-matched, multi-lineage cell panels across diverse populations to support safety, efficacy, and regulatory testing.

1 investor

Biopharmaceutical company using molecular biology to produce recombinant derivatives of botulinum neurotoxin for customized applications.

1 investor

Cytodyme builds software for regulatory and quality teams at life science companies to manage post-market reporting, literature reviews, documentation, audits, and submissions. The platform consolidates data from disconnected systems to reduce administrative burden for regulated life science and biotech teams.

1 investor

Cytokinetics develops potential medicines for cardiovascular and neuromuscular diseases characterized by impaired muscle function. The company specializes in sarcomere-directed therapies targeting conditions involving muscle weakness, loss, and dysfunction.

1 investor

Cytomos develops AuraCyt®, a microelectronics-based biotechnology platform for real-time single-cell analytics in bioprocessing and cell and gene therapy manufacturing. The company serves large biotech and pharma companies seeking cost-effective process analytical technology solutions for drug development and manufacturing.

1 investor

Clinical-stage biotechnology company developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment.

1 investor

Cyto Recovery develops technology for label-free cell sorting and gentle sample cleanup for cell populations, aimed at life-science and research users. Its products are positioned as tools for separating and purifying cells without labeling.

1 investor

Cytos is an orthobiologics company that develops biologic treatments for orthopedic conditions. The company serves orthopedic surgeons and patients requiring spine, foot, ankle, and other orthopedic interventions.

1 investor

Hone Bio is a pre-clinical biotech company developing NanoPilot lipid nanoparticle (LNP) targeting technology for extrahepatic drug delivery, engineering LNPs to target specific cell types while blocking off-target liver uptake. It serves therapeutic developers seeking to deliver treatments such as mRNA-based therapies beyond the liver.

1 investor

Cytovation develops immunotherapy treatments designed to enhance immune response against various cancer types, with a focus on engineered synthetic peptides and first-in-class therapeutic candidates. The company is built on research foundations from Norwegian academic institutions and serves oncology and immunology markets.

1 investor

Cytrellis develops medical device technologies focused on aesthetic and reconstructive treatments, with expertise spanning dermatology, plastic surgery, and wound healing applications.

1 investor

Cytura Therapeutics is a pharmaceutical company focused on drug discovery and development, with backing from academic research institutions and venture capital firms specializing in biotech and medtech investments.

1 investor

1 investor

D2B3 develops proprietary drug delivery technology that temporarily relaxes the blood-brain barrier to enable therapeutic targeting of central nervous system diseases. The platform is designed to work across multiple drug classes for treating brain-related disorders.

1 investor

Data2Discovery builds a knowledge graph and data science software platform that integrates and analyzes large, complex, heterogeneous datasets to surface insights in fields such as drug discovery, disaster medicine, and food science. It serves pharmaceutical, biotech, research, and government organizations, with applications including drug repurposing, toxicology, and phenotypic analysis.

1 investor

Da Capo develops therapies aimed at halting the progression of neurodegenerative disease, using a target and drug discovery platform that combines data analytics, network biology, human iPS cell models, and chemistry and phenotypic screening. It focuses on recapitulating human neurodegenerative biology to identify disease drivers and move from target to lead compound.

1 investor

1 investor

DalCor Pharmaceuticals is a biopharmaceutical company developing dalcetrapib, a pharmacogenetic precision medicine for cardiovascular disease that targets patients with the ADCY9 AA genotype. The drug is being evaluated in Phase 3 clinical trials to reduce fatal and non-fatal myocardial infarction in post-acute coronary syndrome patients.

1 investor

Dalriada is a contract research organization providing integrated small molecule drug discovery services for global biotech and pharmaceutical companies. The company operates an interdisciplinary team under one roof offering full-suite drug discovery expertise from target identification through pre-clinical development.

1 investor

DaltonTx builds an AI-enabled cloud platform for drug discovery, covering the full lifecycle from data ingestion and model training to molecule generation and experiment prioritisation for both biologics and small molecules. It serves pharma, biotech, and CROs, positioning itself as R&D infrastructure that combines human scientific expertise with machine intelligence.

1 investor

Advancing potentially best-in-class therapeutics for myeloproliferative neoplasms.

1 investor

Damora Therapeutics develops targeted monoclonal antibody therapies for rare blood disorders, specifically Essential Thrombocythemia and Myelofibrosis driven by mutant calreticulin mutations. The company is advancing novel subcutaneous biologics to treat approximately 42,000 U.S. patients with these myeloproliferative neoplasms.

1 investor

Danaher is a global science and technology company specializing in biotech, diagnostics, and life sciences with businesses that innovate in drug development, molecular diagnostics, genomic medicine, and bioprocessing to help advance human health. Operating through multiple strategic platforms and with nearly 63,000 employees, Danaher develops technologies and solutions for researchers, biopharmaceutical producers, and healthcare systems globally.

1 investor

Dario provides digital tools and support to help people manage chronic conditions such as diabetes between provider visits. Its platform focuses on day-to-day health management for individuals with one or more chronic conditions, primarily in the U.S.

1 investor